Cingulate (CING) Expected to Announce Quarterly Earnings on Thursday

Cingulate (NASDAQ:CING) will likely be issuing its Q4 2025 results before the market opens on Thursday, March 26th. Analysts expect the company to announce earnings of ($0.56) per share for the quarter. Individuals are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Wednesday, March 18, 2026 at 7:00 AM ET.

Cingulate (NASDAQ:CING) last announced its quarterly earnings data on Wednesday, March 18th. The company reported ($0.84) earnings per share for the quarter, missing the consensus estimate of ($0.56) by ($0.28). On average, analysts expect Cingulate to post $-12 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Cingulate Stock Performance

NASDAQ:CING opened at $6.93 on Tuesday. The stock has a fifty day moving average price of $6.60 and a 200-day moving average price of $4.87. The company has a market cap of $56.48 million, a price-to-earnings ratio of -1.60 and a beta of -0.77. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.16 and a current ratio of 1.16. Cingulate has a fifty-two week low of $3.20 and a fifty-two week high of $11.89.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the company. Roth Mkm decreased their price target on Cingulate from $16.00 to $14.00 and set a “buy” rating on the stock in a research report on Monday. Ascendiant Capital Markets cut their price objective on shares of Cingulate from $62.00 to $58.00 and set a “buy” rating for the company in a research report on Monday, December 8th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Cingulate in a research note on Wednesday, January 21st. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $36.00.

Insider Buying and Selling at Cingulate

In other Cingulate news, CEO Shane J. Schaffer purchased 6,809 shares of the firm’s stock in a transaction dated Friday, February 6th. The shares were bought at an average price of $5.04 per share, for a total transaction of $34,317.36. Following the purchase, the chief executive officer owned 10,175 shares in the company, valued at approximately $51,282. This trade represents a 202.29% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Peter J. Werth purchased 19,455 shares of the stock in a transaction dated Friday, February 6th. The shares were acquired at an average cost of $5.04 per share, with a total value of $98,053.20. Following the acquisition, the director directly owned 117,449 shares in the company, valued at $591,942.96. This represents a 19.85% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have acquired 33,074 shares of company stock valued at $166,693 over the last 90 days. Corporate insiders own 4.33% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of CING. Bank of America Corp DE raised its stake in Cingulate by 283.1% during the second quarter. Bank of America Corp DE now owns 7,501 shares of the company’s stock worth $31,000 after acquiring an additional 5,543 shares in the last quarter. XTX Topco Ltd acquired a new stake in shares of Cingulate in the 2nd quarter valued at approximately $45,000. Quadrature Capital Ltd bought a new stake in shares of Cingulate during the 4th quarter valued at approximately $66,000. DRW Securities LLC bought a new stake in shares of Cingulate during the 4th quarter valued at approximately $255,000. Finally, Geode Capital Management LLC increased its position in Cingulate by 43.9% during the 4th quarter. Geode Capital Management LLC now owns 61,035 shares of the company’s stock worth $265,000 after purchasing an additional 18,629 shares in the last quarter. Institutional investors own 41.31% of the company’s stock.

Cingulate Company Profile

Cingulate Inc, a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company’s stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults.